2 registrations that name bovine colostrum as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
Not yet recruitingNCT07856979
Colostrum and Gut Health
No phase
Bovita Labs, LLC
About 140 people
Starts Sep 4, 2026 (estimated)
In plain words A study of bovine colostrum in people 30 to 60, run by Bovita Labs, LLC. It plans to enroll about 140 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 60; healthy volunteers accepted. Conditions: Gastrointestinal Health.
Adults aged 30 to 60 years at the time of enrollment.
Self-reported suboptimal digestive function (e.g., bloating, irregular bowel habits, discomfort) and/or suboptimal immune function (e.g., frequent colds, low energy) during the previous 4 weeks.
Willing and able to consume a powdered supplement (3-6 g) mixed in liquid once daily.
Own a compatible iOS or Android smartphone with internet access.
5 more inclusion criteria and the exclusion criteria are on the listing.
The primary objective of this study is to evaluate changes in participant-reported gastrointestinal function over a 16-week intervention period and a 4-week non-supplementation period (20 weeks total) following daily consumption of two different doses of colostrum in comparison to a placebo. Secondary objectives include evaluation of digestive comfort, immune resilience, energy levels, sleep quality, hsCRP, metabolic panel, microbiome status and function, and hair and skin health. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07082881
Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants
No phase
Suqian First Hospital
About 220 people
Starts Sep 1, 2025 (estimated)
In plain words A study of bovine colostrum in people 0 days to 1 day, run by Suqian First Hospital. It plans to enroll about 220 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 0 days to 1 day. Conditions: Growth Failure; Preterm Birth; Microbiota.
Gestational age <32 weeks and birth weight <1500 g;
admitted to the NICU of one of the five hospitals mentioned above within 24 h of birth; and
able to initiate the protocol within 72 h of birth and continuously provide adequate colostrum until the end of the protocol.
The exclusion criteria are on the listing.
What it tests, as registered
Colostrum; Normal Saline
Registered summary
The goal of this clinical trial is to ascertain whether oropharyngeal administration of colostrum contributes to postnatal growth in very preterm infants (those born before 32 weeks of gestation). The main questions it aims to answer are: Can Oropharyngeal administration of colostrum effectively lower the incidence rate of extrauterine growth restriction (EUGR) in participants? Does oropharyngeal colostrum intervention bring about changes in the early gut microbiota of participants? Researchers will conduct a comparative analysis between colostrum and a placebo (normal saline) to investigate… The full summary is on the listing.